The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $627,809 project grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to The Trustees of the University of Pennsylvania to conduct research on reprogramming glutamine metabolism in pancreatic beta cells. The objectives are to uncover the mechanisms by which the transaminase GPT2 promotes beta cell dysfunction and death, and elucidate how GPT2 influences the sensitivity of the beta cell to GLP1. This research aims to address gaps in understanding how glucolipotoxicity leads to beta cell dysfunction and death, with the goal of developing strategies to protect beta cells during metabolic stress and enhance sensitivity to GLP1 receptor agonists. The award period is from December 1, 2024 to November 30, 2028.
Generated 3/25/25, 1:55 AM